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Abstract  
Thiazide diuretics, commonly used antihypertensives, may cause QT interval (QT) 
prolongation, a risk factor for highly fatal and difficult to predict ventricular arrhythmias.  We 
examined whether common SNPs modified the association between thiazide use and QT or its 
component parts (QRS interval, JT interval) by performing ancestry-specific, trans-ethnic, and 
cross-phenotype genome-wide analyses of European (66%), African American (15%), and 
Hispanic (19%) populations (N=78,199), leveraging longitudinal data, incorporating corrected 
standard errors to account for underestimation of interaction estimate variances and evaluating 
evidence for pathway enrichment.  Although no loci achieved genome-wide significance 
(P<5x10-8), we found suggestive evidence (P<5x10-6) for SNPs modifying the thiazide-QT 
association at 22 loci, including ion transport loci (e.g. NELL1, KCNQ3).  The biologic 
plausibility of our suggestive results and simulations demonstrating modest power to detect 
interaction effects at genome-wide significant levels indicate that larger studies and innovative 
statistical methods are warranted in future efforts evaluating thiazide-SNP interactions. 
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 Over the past decade, the use of prescription drugs has skyrocketed, with nearly half of 
all Americans now taking at least one prescription drug.1  Accompanying the increased 
prevalence of drug use is a high burden of adverse drug reactions (ADRs), which account for 
approximately 100,000 deaths and 2.2 million serious health effects annually.2-4  QT interval 
(QT) prolongation, which can trigger fatal ventricular arrhythmias, is a long-recognized adverse 
effect5 of numerous common medications such as antipsychotics, antibiotics, antiarrhythmics, 
and antihypertensives.6  Within the past ten years, QT prolongation has represented the most 
common cause for withdrawal of a drug from the market (or relabeling) after approval by the 
U.S. Food and Drug Administration (FDA).7, 8  However, drug-induced QT prolongation remains 
difficult to predict.9    
 Genetic variants are known to mediate both pharmacokinetic and pharmacodynamic 
processes, thereby playing a major role in drug response. 10  Pharmacogenomics, which evaluates 
the role of genetics in drug response, offers a promising avenue for understanding variation in 
drug response,11 illuminating novel pathways, informing drug development and selection,12-14 
optimizing dosing regimens,15-19 and avoiding ADRs.20-22  QT is highly heritable (35-40%).23-27 
Previous pharmacogenomics studies of drugs associated with QT prolongation, including 
thiazide diuretics, a common antihypertensive therapy used by over a quarter of the U.S. 
hypertensive population,28 identified multiple loci associated with anti-hypertensive response and 
ADRs.29-34  Furthermore, thiazide diuretics are used disproportionately across race/ethnic groups 
in the U.S., with approximately 10% of Hispanic/Latinos, 13% of European Americans, and 23% 
of African Americans taking a thiazide diuretic.28, 35, 36  Therefore, the pharmacogenomics of 
thiazide-induced QT prolongation represents an excellent but understudied candidate for 
pharmacogenomic inquiry. 
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 We previously examined evidence for common single nucleotide polymorphisms (SNPs) 
that modified the association between thiazide use and QT and failed to identify any genome-
wide significant loci (P<5x10-8).37  However, our previous study was limited to European 
descent populations and cross-sectional analyses, despite many of the contributing studies having 
longitudinal drug and electrocardiographic data.37  Here, we expand upon that work, applying 
recent statistical innovations to leverage longitudinal data and including an additional 44,418 
participants of European, African American, and Hispanic/Latino descent to perform the first 
trans-ethnic genome-wide association study (GWAS) to examine genetic associations that 
modify the association between thiazides and QT, as well as the component parts of QT (JT 
interval [JT], QRS interval [QRS]).  
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Materials and Methods 
Study Populations 
 Fourteen cohorts participated in this analysis from in the Cohorts for Heart and Aging 
Research in Genomic Epidemiology (CHARGE)38 Pharmacogenomics Working Group (PWG), 
contributing 78,199 participants: European descent (51,601), African American (11,482), and 
Hispanic/Latino (15,116) participants (Table 1, Supplementary Text).   Among the fourteen 
cohorts, six (55% of the total population) had repeated measurements of medication use and 
electrocardiogram (ECG) assessments and contributed longitudinal data to the analysis: Age, 
Gene/Environment Susceptibility – Reykjavik Study (AGES), Atherosclerosis Risk in 
Communities (ARIC) Study, Cardiovascular Health Study (CHS), Rotterdam Study (RS), Multi-
Ethnic Study of Atherosclerosis (MESA), and Women’s Health Initiative (WHI).  The remaining 
eight cohorts contributed cross-sectional data to the analysis: Framingham Heart Study (FHS), 
Erasmus Rucphen Family (ERF) Study, Health 2000, Health, Aging, and Body Composition 
(Health ABC), Prospective Study of Pravastatin in the Elderly at Risk (PROSPER), Jackson 
Heart Study (JHS), Netherlands Epidemiology of Obesity (NEO) Study, and Hispanic 
Community Health Study/Study of Latinos (HCHS/SOL). 
Study Design 
 Participants with ECG measurements, medication assessment, and genome-wide 
genotype data were eligible for inclusion.  The following exclusion criteria were applied: poor 
ECG quality, atrial fibrillation detected by ECG, pacemaker implantation, second or third degree 
atrioventricular heart block, QRS greater than 120 milliseconds (ms), prevalent heart failure, 
pregnancy, missing ECG, missing medication assessment, missing genotype information, or 
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race/ethnicity other than European descent, African American, or Hispanic/Latino.  For studies 
with longitudinal data, exclusion criteria were applied on a visit-specific basis. 
Medication Assessment 
 Medication use was assessed through medication inventories conducted during clinic 
visits or home interviews or through pharmacy databases (Supplementary Table 1).  Six studies 
captured medication used on the day of the study visit.  A further six of the 14 participating 
cohorts captured medications used one to two weeks preceding ECG assessment.  HCHS/SOL 
ascertained medications used within four weeks preceding ECG measurement and the RS 
captured medication used within 30 days preceding ECG assessment.  Participants were 
classified as thiazide diuretic users if they took a thiazide or thiazide-like diuretic in a single or 
combination preparation, with or without potassium (K)-sparing agents, and with or without K-
supplements.  
For cross-sectional studies, the number of exposed participants (Nexposed) was defined as 
the number of participants classified as thiazide users.  For studies with longitudinal data, Nexposed 
was calculated as follows: 
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where ni is the number of observations for participant i, ˆ  is an estimate of the pairwise visit-to-
visit correlation within participants from a Generalized Estimating Equation (GEE)-
exchangeable model that does not contain genetic data, and  1# itE  is the number of 
observations for which participant i was exposed.39 
7 
 
ECG Interval Measurement 
 QT and QRS were digitally recorded by each participating study using resting, supine or 
semi-recumbent, standard 12-lead ECGs (Supplementary Table 2).  Comparable procedures were 
used for preparing participants, placing electrodes, recording, transmitting, processing, and 
controlling quality of ECGs.  Studies used Marquette MAC 5000, MAC 12, MAC 1200, or MAC 
PC (GE Healthcare, Milwaukee, Wisconsin, USA), University of Glasgow (Cardiac Science, 
Manchester, UK), or ACTA (EASOTE, Florence, Italy) machines.  Recordings were processed 
using one of the following programs (Marquette 12SL, MEANS, University of Glasgow, digital 
calipers, or Health 2000 custom-made software.  JT was calculated by the formula: JT=QT–
QRS. 
Genotyping and Imputation 
 Each study conducted genome-wide genotyping independently using either Affymetrix 
(Santa Clara, CA, USA) or Illumina (San Diego, CA, USA) arrays (Supplementary Table 3).  
Sex mismatches, duplicate samples, and first-degree relatives (except in ERF, FHS, HCHS/SOL, 
and JHS) were excluded.  DNA samples with call rates less than 95-98% were excluded as were 
SNPs with SNP call rates less than 90-98%, minor allele frequencies (MAF) less than 1%, or that 
failed Hardy-Weinberg equilibrium.  To maximize genome coverage and comparisons across 
genotyping platforms, genotypes were imputed using HapMap2,40-42 1000 Genomes Phase 1, or 
1000 Genomes Phase 3 reference panels.43, 44  Genotypes imputed using build 37 were lifted over 
to build 3645, 46 to enable comparisons between imputation platforms and results were restricted 
to SNPs present in HapMap2. 
Statistical Analyses 
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 Genome-wide pharmacogenomic analyses were performed by each cohort independently 
across approximately 2.5 million SNPs for QT, QRS, and JT separately.  Drug-SNP interactions 
were estimated assuming an additive genetic model, using mixed effect models, GEE, or linear 
regression with robust standard errors.  The analytic model varied based on study design and the 
availability of longitudinal data (Supplementary Table 4).  All analyses were adjusted for age 
(years), sex when applicable, study site or region, principal components of genetic ancestry, 
visit-specific RR interval (ms), and visit-specific QT altering medications defined using the 
University of Arizona Center for Education and Research on Therapeutics (UAZ CERT) QT-
prolonging drug classification.6  Furthermore, ERF, FHS, and HCHS/SOL incorporated 
estimates of relatedness into all analyses.  Study-specific results were corrected for genomic 
inflation (λ). 
 Previous simulations demonstrated that models using robust standard errors 
underestimate the variance of coefficient estimates for SNPs with low MAFs.39  To account for 
this underestimation, corrected standard errors were calculated using a (Student’s) t-reference 
distribution.39  The degrees of freedom (df) for the t-reference distribution were estimated using 
Satterthwaite’s method.47  When cohorts were unable to implement Satterthwaite’s method, an 
approximate df was calculated as twice the cohort- and SNP-specific product of the SNP 
imputation quality (range: 0,1), the MAF (range: 0.0,0.50), and Nexposed.  Standard errors were 
then “corrected” by assuming a normal reference distribution that yielded the t-distribution based 
P-values from the beta estimates.39  Furthermore, because simulations demonstrated that 
corrected standard errors were unstable when minor allele counts among the exposed were low, a 
cohort-specific df filter of 15 was applied across all SNPs.39 
9 
 
 For each trait, race-stratified and trans-ethnic betas and corrected standard errors were 
combined with inverse-variance weighted meta-analysis conducted in METAL.48  We used a 
genome-wide significance threshold of P<5x10-8 and a suggestive threshold of P<5x10-6.  
However, the assumptions of a fixed-effects meta-analysis do not always hold between 
race/ethnicities due to differences in patterns of linkage disequilibrium (LD) across ancestral 
populations, potential allelic heterogeneity, differences in gene-environment and gene-gene 
interactions, and differences in environmental and lifestyle factors.49, 50  Therefore, trans-ethnic 
meta-analysis was also conducted using the Bayesian MANTRA approach and a genome-wide 
threshold of log10(Bayes Factor [BF])>6 and a suggestive threshold of log10(BF)>5.
51  
Additionally, previous studies have demonstrated the potential to increase power and detect 
evidence of pleiotropy by conducting multi-trait analysis across correlated traits.52, 53  To 
examine potential pleiotropy across ventricular depolarization and repolarization, we conducted 
cross-phenotype meta-analysis combining t-statistics across QRS and JT using an adaptive sum 
of powered score (aSPU) test, which tests for both concordant and discordant associations across 
some or all of the included traits.54  The reference distribution for the aSPU test was calculated 
using 108 simulations.   
 Genome-wide significant and suggestive meta-analysis results were examined for gene or 
pathway enrichment.  Previous work has shown that it is beneficial to apply multiple methods of 
gene-set analysis (GSA) when the underlying etiology of the genetic mechanism is unclear.55-57   
We therefore used two methods of GSA.  We performed a multiple regression gene analysis 
approach followed by a self-contained GSA using gene-level regression as implemented in 
MAGMA.58  Post-meta-analysis P-values were used as input in the analysis and gene-sets were 
collected from Ingenuity,59 Panter,60 KEGG,61 and ConsensusPathDB62, 63 and restricted to 
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biologically motivated pathways involved in the following: ion transport and homeostasis, 
transcription and translation, renal and cardiac development and function, and 
pharmacokinetic/dynamic pathways.  Additionally, we selected all SNPs with P<1x10-5 for 
analysis with DEPICT, which searches for gene, gene-set, and tissue enrichment among 14,461 
reconstituted gene-sets, eliminating the need to select candidate gene-sets.64  To account for 
multiple testing, we applied a false discovery rate (FDR) threshold of 5% for both GSA 
approaches.   
Statistical Power Simulations 
 Power to detect drug-SNP interactions using cross-sectional and longitudinal modeling 
approaches was estimated via simulation studies.  Assumptions, which were informed by 
European ancestry populations, included: (1) 50,000 participants; (2) a two-sided, per-SNP 
α=5x10-8; (3) a mean heart rate-corrected QT (standard deviation)=400 (30) ms; (4) 
Nexposed=8,100; (5) a mean drug effect for those with zero copies of the minor allele=5 ms; (6) a 
mean SNP effect for those not exposed to drug=0 ms; (7) a MAF=0.05 or 0.25; (8) an additive 
model of inheritance; (9) two study visits for longitudinal simulations; (10) within-person QT 
correlation=0.80; (11) an attrition rate between visits for longitudinal simulations=0.13; (12) 
random missingness rate across study visits=0.09; and (13) an independent GEE correlation 
structure for longitudinal simulations.  For longitudinal simulations, drug use was either 
temporally constant or variable.  When variable, drug exposure was assumed to be completely 
random at both visits.  
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Results 
Study Characteristics 
 A total of 78,199 participants were included in the analysis, of which 13,730 (18%) were 
exposed to thiazides (Table 1).  Thiazide use was most common among African Americans 
(36%), compared with 16% and 9% among European descent and Hispanic/Latino populations, 
respectively.  Mean age ranged from 40 (FHS) to 75 years (PROSPER) and the percentage of 
females ranged from 47% (NEO, PROSPER) to 100% (WHI).  Average QT was between 389 ms 
(H2000) and 416 ms (HCHS/SOL).  
Genome-Wide Analysis of Thiazide-SNP Interaction and QT Interval 
 Q-Q plots for individual study results, as well as for meta-analyzed results, demonstrated 
adequate calibration of study specific test statistics (Supplementary Figures 1-4).  However, the 
family-based studies (ERF, FHS, HCHS/SOL) showed modest evidence of over-dispersion 
(λ=1.07 – 1.16).   
 No genome-wide significant thiazide-SNP interaction effects were detected in any 
race/ethnic group (Figure 1).  However, suggestive interaction effects (P<5x10-6) were found for 
22 loci in at least one race/ethnic group: European descent (seven loci), African American (six 
loci), Hispanic/Latino (six loci), or trans-ethnic (nine loci) (Figure 1, Table 2).  Only the 
DNAH8/BTBD9 locus was suggestively significant in more than one race/ethnic group (rs862433 
in African Americans, rs1950398 in Hispanic/Latinos).  Only two of the suggestive SNPs were 
heterogeneous across populations with Phet<0.05 (rs4890550 and rs13223427).   
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Additionally, examination of 35 loci previously associated with QT in a published main 
effects GWAS65 found no significant associations in European descent populations using a 
Bonferroni corrected threshold of P<0.001 (0.001=0.05/35; Supplementary Table 5).  The 
magnitude of the interaction effect was close to zero for all but six of the 35 SNP, which had 
interaction effects greater than 0.50 ms.   
 Similarly, while no locus showed genome-wide significance in our trans-ethnic 
MANTRA analysis (Supplementary Figure 5), one SNP (rs2765279) was above the suggestive 
threshold, with a log10(BF) of 5.2.  Rs2765279, located in RGSL1, a gene involved in G-protein 
signaling regulation, was also the most significant SNP in the fixed-effects trans-ethnic analysis 
(P=3x10-7). 
Genome-Wide Analysis of Thiazide-SNP Interaction and QRS Interval or JT Interval 
 Results for QRS showed a similar pattern to those for QT (Supplementary Figure 6, 
Supplementary Table 6).  Whereas no results achieved genome-wide significance, 28 loci 
showed suggestive evidence of modifying the thiazide-QRS association (four loci in European 
descent populations, 11 in African Americans, eight in Hispanic/Latinos, and seven in trans-
ethnic populations) and only one SNP had a Phet<0.05 (rs11591185).  The most significant SNP, 
rs7638855 (P=2x10-7), located upstream from GAP43, was also suggestively significant after 
trans-ethnic analysis in MANTRA (log10(BF)=5.4; Supplementary Figure 5).   
 Similarly, no SNPs showed genome-wide significant interaction for JT, although 19 loci 
were suggestively associated (five loci in European descent populations, four in African 
Americans, five in Hispanic/Latino, and seven in trans-ethnic populations; Supplementary Figure 
6, Supplementary Table 7).  No SNPs showed significant heterogeneity between populations.  
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Moreover, MANTRA analysis identified two SNPs that achieved suggestive significance 
(Supplementary Figure 5).  The rs1264878 variant near KCNIP4, a voltage-gated potassium 
channel interacting protein was the most significant SNP in our fixed-effects meta-analyses 
(P=3x10-7) and had a log10(BF)=5.1.  However, most significant SNP in MANTRA meta-
analyses was rs9303589, in CA10, with a log10(BF)=5.1. 
Cross-Phenotype Meta-Analysis 
 Cross-phenotype meta-analysis found no genome-wide significant evidence of pleiotropy 
across QRS and JT (Figure 2, Supplementary Figure 7).  However, eight loci had a suggestive 
evidence of thiazide-SNP interaction after meta-analyzing QRS and JT results (Table 3).  These 
included three loci that were nominally associated with QRS and JT (P<0.05), but whose effects 
did not reach the suggestive association threshold in either univariate analysis (rs1295230 
[PIK3R6], rs6931354 [ADGRB3], and rs8119517 [PREX1]).   
Gene and Pathway Enrichment Analysis 
 Although analysis with DEPICT found no enrichment in a single gene or tissue, gene-set 
enrichment analysis in European descent populations found enrichment in the ATXN3 
subnetwork for the interactive effect of genotype and thiazide use on QT (P=1x10-6).  There was 
no enrichment found in QRS or JT analyses.  MAGMA analyses found significant enrichment in 
six genes among African Americans in the interactive effect of genotype and thiazide use on 
QRS: CNTRL, CPN1, FAM65B, RAB14, ISY1, NELL1 (Supplementary Table 8).  No other 
MAGMA analyses found gene enrichment.  MAGMA GSA for QT and JT analyses found 
significant enrichment for transcription and translational pathways, although no gene-set 
enrichment was found in QRS analyses (Table 4). 
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Statistical Power 
 Given the biologic plausibility of the suggestive results for all three traits, we examined 
statistical power for our analysis to assess our ability to detect interaction effects.  Simulations 
demonstrated that all analyses were underpowered to detect thiazide-SNP interaction effects less 
than 3 ms (e.g. 15% power to detect an interactive effect of 2 ms; Figure 3).  However, even with 
time-varying drug exposure (i.e. observed QT measurement on and off drug within an 
individual), which demonstrated the greatest power, analyses for SNPs with MAF=5% did not 
achieve 80% power until the thiazide-SNP interaction effect reached 6 ms.   
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Discussion 
 In this study, we examined 78,199 participants of European, African American, or 
Hispanic/Latino descent for evidence of thiazide-SNP interactions influencing QT.  Although we 
used a comprehensive approach that considered multi-ethnic populations, leveraged pleiotropy, 
accommodated population heterogeneity, and examined QT as well as its component parts (QRS, 
JT), we did not identify any genome-wide significant SNPs modifying the association between 
thiazides and these ECG intervals.  However, we identified 74 loci with suggestive evidence of 
association through either univariate or cross-phenotype analyses as well as evidence of 
enrichment in pathways involved in transcription and translation.   
Interestingly, our suggestive results included multiple loci involved in ion transport and 
handling, the disruption of which is believed to be an underlying mechanism in drug-induced QT 
prolongation,66 supporting the hypothesis that common SNPs modify the thiazide-QT 
relationship.  For example, the NELL1 locus was previously associated with changes in fasting 
plasma triglyceride levels in response to hydrochlorothiazide use.67  Other interesting suggestive 
results include the PITX2 and RYR3 QRS loci identified in Hispanic/Latinos, which may directly 
regulate ion channel genes and genes involved in calcium handling.68  Moreover, we found 
suggestive evidence of thiazide-SNP interactions on QT, QRS, or JT in other genes involved in 
ion transport and handling, including STC2,69 EDN1,70 TRPC7,71 PKP2,72 and DISC1,73 as well 
as a voltage-gated potassium channel gene (KCNQ3).   
 Despite these intriguing results, our power simulations suggested there was limited power 
to detect interaction effects of 2 ms, sizes consistent with QT main effects analyses.65 The low 
power suggests that larger sample sizes and/or innovative statistical methods may be required to 
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study gene-environment interactions given the stringent genome-wide significance threshold.74-76  
Furthermore, our power simulations demonstrated insufficient power to detect interaction effects 
of 5 ms or less for less common SNPs (MAF=5%).  Therefore, future work should utilize larger 
sample sizes, particularly studies with longitudinal data, if available.   
 Another limitation of our work was that medication use data were collected infrequently, 
e.g. years apart.  Particularly, medication assessments covered only one to two weeks of 
medication use in most participating cohorts and variables such as medication dosage and 
duration of use were not available universally across studies.  Previous work has demonstrated a 
dose-dependent relationship between thiazide use and cardiac arrest, a potential outcome of QT 
prolongation.77  However, we were unable to identify participants using high dose thiazides 
because medication dosage data was unavailable in all cohorts.  Furthermore, K+ measurements 
and information on K+ supplements was not obtained across all cohorts so we were unable to 
adjust for K+ levels in our analyses, despite the known role of thiazide diuretics in inducing 
hypokalemia and the role of hypokalemia in causing QT prolongation.78, 79 
 Furthermore, ECG intervals are known to vary in the presence of cardiovascular disease 
(CVD).80  While we did exclude CVD metrics like prevalent heart failure and atrial fibrillation, 
we were not able to further characterize the role of CVD in the pharmacogenomics of thiazide 
use and QT duration.  Given that we saw larger mean QT and JT intervals in Hispanic/Latino 
populations than in European descent or African American populations in our study sample, as 
well a substantial difference in mean exposure to thiazides, ranging from just 9% in 
Hispanic/Latinos to 37% in African Americans, our analyses are limited by the heterogeneity of 
exposure and outcome in our population.  The large difference in thiazide exposure between 
race/ethnic groups could also indicate an underlying difference in CVD prevalence among our 
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populations.  Considering that pharmacogenomic studies such as this one are already limited in 
their power to detect effects, the addition of unmeasured heterogeneity such as CVD status could 
further reduce our power to detect genetic effects modifying the relationship between thiazides 
and QT.  Therefore, future work should consider alternate study designs, such as clinical trials or 
specially collected cohorts, as settings for pharmacogenomics work.  In clinical trials or specialty 
cohorts, populations can be more closely controlled and therefore more homogeneous in traits 
that may confound the relationship between thiazides and QT.     
Additionally, observational cohort studies are known to be susceptible to selection biases, 
such as prevalent user bias, whereby long-term medication users are least likely to suffer from 
ADRs and users with ADRs often stop therapy and therefore have a lower chance of being seen 
while on therapy.81, 82  Unfortunately, without duration of use metrics, it remains difficult to 
assess the effects of prevalent user bias on study results.  Indeed, it is unclear if these biases are 
of concern in pharmacogenomic studies.83, 84  Additional work is needed to assess whether 
selection bias requires more consideration in pharmacogenomic research and to assess possible 
advantages of alternative designs, such as active comparator designs (whereby the control group 
contains participants using a different class of medications with similar indications to the 
medication of interest) or new user designs (whereby prevalent users are excluded).   Moreover, 
medication inventories may be associated with non-negligible measurement error.  For example, 
while Smith et al. reported good agreement between thiazide use measured using medication 
inventories and serum thiazide measurements, specificity remained moderate. 85   
 Given the challenges associated with assembling an adequately powered 
pharmacogenomics study, electronic medical records (EMRs) represent a potential untapped 
resource that may merit evaluation.  Strengths of EMRs include the potential to provide a more 
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complete medication history, which could enable sensitivity analyses examining variables such 
as medication dose and duration of use.  Furthermore, consortia such as eMERGE have 
demonstrated the feasibility of linking EMRs to genetic data for use in genetic research,86 and 
have successfully identified genetic variants modifying drug response.87  However, EMRs have 
limitations.  Investigators using EMR data cannot control participant recruitment, timing and 
accuracy of data collection, or population representativeness.88  Considering ECG research 
specifically, cohort studies administer ECGs to all participants at study visits, whereas EMRs 
may capture ECGs for patients with medical indications, providing an inherently different 
population.  EMRs therefore have the potential to greatly advance pharmacogenomic research 
but warrant further evaluation. 
 In conclusion, our findings suggest that additional work is needed to fully elucidate 
potential pharmacogenomic effects influencing the thiazide-QT relationship.  Our suggestive 
results support a possible role of genetics in modifying the association between thiazides and 
QT.  However, these findings can inform the biology of thiazide-induced QT-prolongation and 
do not preclude the possibility of common variants with small effects or rare variants with larger 
effects.  Future work that leverages larger sample sizes, such as those available in EMRs, and 
innovative statistical methods to validate these suggestive findings is needed.  The FDA 
considers further regulation of drugs that prolong QT by as little as 5 ms, a small increment 
easily achieved by the combination of genetic and pharmaceutical effects,37, 89 making it critical 
that we unravel the complex etiology of drug-induced QT prolongation.90  Pharmacogenomics 
remain a promising avenue for understanding variability in drug response and for utilizing 
genetics to improve public health but innovative solutions are needed to overcome inherent 
challenges.   
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Figure Legends 
Figure 1.  Manhattan plots of P-values for thiazide-SNP interaction estimates for QT interval 
analyses after fixed effects meta-analysis among European descent populations (N = 51,601), 
African American populations (N = 11,482), Hispanic/Latino populations (N = 15,116), and all 
populations (trans-ethnic).  Each study was analyzed using linear regression, mixed-effects 
models, or generalized estimating equations and SNPs with a study-specific degree of freedom 
measure (df = twice the cohort- and SNP-specific product of the SNP imputation quality (range: 
0,1), the MAF (range: 0.0,0.50), and the number of individuals exposed to thiazide [Nexposed]) < 
15 were excluded from meta-analysis.  The x-axis represents the chromosomal position and the 
y-axis represents the –log10(P-value).   On each plot, genome wide significance (P < 5x10-8) and 
suggestive significance (P < 5x10-6) are denoted with dashed lines. 
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Figure 2.  Manhattan plots of P-values thiazide-SNP interaction estimates after cross-phenotype 
meta-analysis (QRS interval, JT interval) using aSPU among European descent populations (N = 
47,836), African American populations (N = 11,482), and Hispanic/Latino populations (15,116).    
For each trait separately, each study was analyzed using linear regression, mixed-effects models, 
or generalized estimating equations and SNPs with a study-specific degree of freedom measure 
(df = twice the cohort- and SNP-specific product of the SNP imputation quality (range: 0,1), the 
MAF (range: 0.0,0.50), and the number of individuals exposed to thiazide [Nexposed]) < 15 were 
excluded from cross-phenotype meta-analysis.  The x-axis represents the chromosomal position 
and the y-axis represents the –log10(P-value).   On each plot, genome wide significance (P < 
5x10-8) and suggestive significance (P < 5x10-6) are denoted with dashed lines. 
 
Figure 3.  Statistical power of a simulated pharmacogenomics study of QT.  The x-axis 
represents the range of tested drug-SNP interaction effects in milliseconds (ms).  The y-axis 
represents the power to detect the tested drug-SNP interaction effect.  The following assumptions 
were used for the calculations: 2 serial visits measuring electrocardiograms (ECGs) and drug 
exposure, N=50,000 participants, a single-nucleotide polymorphism (SNP) minor allele 
frequency (MAF) of 5% or 25%, and the Nexposed = 8,100.  Simulation analyses were run using 
only the baseline visit (cross-sectional) and a longitudinal model.  Under the longitudinal model, 
simulations were run with all participants having constant drug exposure across visits or having 
varied drug exposure across visits.  Cross-sectional models were run using linear regression and 
longitudinal models were run using a generalized estimating equation with an independence 
working correlation. 
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Table1.  Study Population Characteristics of 25 Contributing Study Populations 
Population Nexposed Ntotal 
QT in ms, 
mean (SD) 
QRS in 
ms, mean 
(SD) 
JT in ms, 
mean 
(SD) 
Age in years, 
mean (SD) 
Female, 
% 
European Descent        
AGES 435 2,256 405 (34) 90 (10) 316 (33) 75 (5) 64.2 
ARIC 1,449 8,567 399 (29) 91 (10) 308 (29) 54 (6) 52.6 
CHS 1,003 3,004 414 (32) 88 (10) 322 (30) 72 (5) 62.5 
ERF 29 1,792 398 (28) NA NA 48 (14) 59.0 
FHS 83 3,168 415 (30) 88 (10) 328 (30) 40 (9) 52.5 
H2000 104 1,973 389 (30) NA NA 50 (11) 52.0 
Health ABC 217 1,560 414 (32) 90 (11) 324 (32) 74 (3) 49.4 
MESA 453 2,216 412 (29) 93 (9) 320 (29) 62 (10) 52.1 
NEO 609 5,366 406 (29) 93 (10) 313 (29) 56 (6) 47.0 
PROSPER 1,175 4,556 414 (36) 94 (11) 320 (35) 75 (3) 47.0 
RS I 523 4,805 397 (29) 97 (11) 300 (28) 69 (9) 60.2 
RS II 161 1,889 403 (28) 98 (11) 305 (28) 65 (8) 56.6 
RS III 93 1,950 401 (26) 98 (11) 304 (26) 56 (6) 54.1 
WHI GARNETa 431 1,981 401 (29) 86 (9) 315 (29) 66 (7) 100 
WHI MOPMAPa 268 1,383 402 (30) 86 (8) 316 (30) 63 (7) 100 
WHI WHIMSa 1,106 5,135 401 (30) 86 (9) 315 (29) 68 (6) 100 
Summary 8,139 51,601      
African American        
ARIC 916 2,169 400 (33) 90 (10) 310 (32) 53 (6) 62.3 
CHS 351 666 409 (35) 88 (11) 317 (36) 73 (6) 64.4 
Health ABC 268 1,151 411 (35) 88 (11) 322 (34) 73 (3) 57.6 
JHS 463 1,862 410 (32) 92 (10) 319 (30) 50 (12) 60.9 
MESA 467 1,464 410 (32) 91 (10) 319 (31) 62 (10) 54.4 
WHI SHARe 1,661 4,170 401 (34) 85 (9) 316 (33) 61 (7) 100 
Summary 4,215 11,482      
Hispanic/Latino        
HCHS/SOL 941 12,024 416 (28) 91 (10) 325 (29) 46 (14) 59.5 
MESA 211 1,316 409 (30) 91 (10) 318 (30) 61 (10) 51.8 
WHI SHARe 224 1,776 401 (30) 86 (9) 316 (30) 60 (6) 100 
Summary 1,376 15,116      
Abbreviations: AGES, Age, Gene/Environment Susceptibility – Reykjavik Study; ARIC, Atherosclerosis Risk in 
Communities; CHS, Cardiovascular Health Study; ERF, Erasmus Rucphen Family Study; FHS, Framingham Heart 
Study; GARNET, Genome-wide Association Research Network into Effects of Treatment; HCHS/SOL, Hispanic 
Community Health Study/Study of Latinos; Health ABC, Health, Aging, and Body Composition Study; JHS, 
Jackson Heart Study; JT, JT interval; MESA, Multi-Ethnic Study of Atherosclerosis; MOPMAP, Modification of 
Particulate Matter-Mediated Arrhythmogenesis in Populations; NEO, the Netherlands Epidemiology of Obesity; 
Nexposed, Number of participants exposed to thiazides; Ntotal, Total number of participants in study population after 
exclusions; PROSPER, Prospective Study of Pravastatin in the Elderly at Risk; QRS, QRS interval; QT, QT 
interval; RS, Rotterdam Study; SD, Standard deviation; SHARe, The SNP Health Association Resource; WHI, 
Women’s Health Initiative; WHIMS, the WHI Memory Study 
aGARNET, MOPMAP, and WHIMS represent three independently genotyped WHI samples with non-overlapping 
populations 
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Table 2.  Loci with Suggestive Evidence of Association with the Thiazide-SNP Interaction 
Effect on QT Interval 
Locus SNP Chr Positiona CA CAF 
Interaction Effect 
in ms (SE) P Phet 
European Descent         
KIAA2013 rs17367934 1 11890791 A 0.89 2.4 (0.5)  2x10-6 0.9 
SLC14A2 rs4890550 18 41409189 C 0.44 -1.4 (0.3)  3x10-6 0.01 
RPS29 rs10143493 14 47999650 A 0.01 -10.6 (2.3)  3x10-6 0.4 
NELL1 rs12225793 11 21057283 T 0.12 2.3 (0.5)  4x10-6 1.0 
STC2 rs10079004 5 172704698 A 0.71 -1.5 (0.3)  4x10-6 0.4 
LCLAT1 rs7608507 2 30447424 A 0.75 1.6 (0.3)  4x10-6 0.7 
PPP1R3A rs13223427 7 113199332 T 0.56 1.4 (0.3)  4x10-6 0.02 
African American         
ZBTB16 rs10789991 11 113424299 T 0.03 12.3 (2.4)  5x10-7 0.6 
DNAH8 rs862433 6 38968057 A 0.25 -2.6 (0.5)  7x10-7 0.2 
Intergenic rs9376483 6 140352934 T 0.94 7.2 (1.4)  7x10-7 0.5 
CASP8AP2 rs7753194 6 90597484 A 0.02 -11.4 (2.4)  3x10-6 0.2 
EBF1 rs11135035 5 157833407 A 0.41 2.1 (0.5)  4x10-6 0.9 
LAMA4 rs6926485 6 112630302 T 0.64 2.4 (0.5)  5x10-6 0.5 
Hispanic/Latino         
SPDYA rs12475612 2 28883510 T 0.48 -3.5 (0.7)  1x10-6 0.9 
BTBD9 rs1950398 6 38666897 T 0.97 9.6 (2.0)  2x10-6 0.05 
TDRP rs6558894 8 480495 C 0.14 -4.9 (1.0)  2x10-6 0.3 
COLCA2 rs10749974 11 110696967 A 0.09 -6.0 (1.3)  3x10-6 0.2 
CRYGGP rs17868255 2 51884417 A 0.97 10.3 (2.2)  3x10-6 0.5 
RYR3 rs16968694 15 31376213 A 0.18 4.5 (1.0)  3x10-6 1.0 
Trans-Ethnic         
RGSL1 rs2765279 1 180693520 T 0.28 1.4 (0.3)  3x10-7 0.4 
ZBTB16 rs10789991 11 113424299 T 0.03 12.3 (2.4)  5x10-7 0.6 
PPP1R3A rs17619887 7 113142601 A 0.47 1.2 (0.3)  2x10-6 0.07 
KIAA2013 rs17367934 1 11890791 A 0.89 2.3 (0.5)  2x10-6 1.0 
LCLAT1 rs6756908 2 30446501 A 0.65 1.3 (0.3)  2x10-6 0.5 
FAR1 rs7130476 11 13711632 C 0.90 2.0 (0.4)  3x10-6 0.5 
CASP8AP2 rs7753194 6 90597484 A 0.02 -11.4 (2.4)  3x10-6 0.2 
SMARCA2 rs1886261 9 2163590 A 0.75 1.5 (0.3)  3x10-6 0.9 
ZKSCAN8 rs13205911 6 28232093 T 0.09 -2.5 (0.5)  5x10-6 0.6 
Abbreviations: CA, Coded allele; CAF, Coded allele frequency; Chr, Chromosome; P, P-value; Phet, P-value of 
heterogeneity; SE, Standard error; SNP, Single nucleotide polymorphism 
aBuild 36 Base-Pair Position 
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Table 3.  Loci with Suggestive Evidence Modifying the Effect of Thiazide on QRS and JT 
Intervals After Cross-Phenotype Meta-Analysis 
Locus SNP Chr Positiona CA CAF P 
Univariate P-value 
QRS JT 
European Descent        
PIK3R6 rs1295230 17 8682305 T 0.02 3x10-6 0.008 0.001 
African American        
ADGRB3 rs6931354 6 69527128 A 0.21 1x10-7 0.005 0.0002 
ADCY8 rs10108730 8 131767803 T 0.79 2x10-6 1x10-5 0.0003 
PREX1 rs8119517 20 46464282 A 0.94 3x10-6 0.0005 0.02 
CDH13 rs11649358 16 81415652 A 0.75 5x10-6 9x10-6 0.001 
Hispanic/Latino         
AK2 rs11591185 1 33274771 A 0.07 2x10-6 7x10-7 3x10-5 
ASS1P14 rs12578228 12 33030528 T 0.10 2x10-6 2x10-6 2x10-5 
GALNT13 rs17553946 2 155055407 A 0.23 4x10-6 0.005 9x10-7 
Abbreviations: CA, Coded allele; CAF, Coded allele frequency; Chr, Chromosome; JT, JT interval; P, P-value; 
QRS, QRS interval; SE, Standard error; SNP, Single nucleotide polymorphism 
aBuild 36 Base-Pair Position 
 
 
 
 
Table 4.  Gene-Sets with Enrichment for Genotype-Thiazide Interaction Effects 
Trait Population Gene-Set P FDR 
QT Hispanic/Latino Nucleotide Binding 5x10-6 0.004 
  Metal Ion Binding 6x10-6 0.004 
  tRNA Adenine-N1 Methyltransferase Activity 6x10-5 0.03 
  Transcription Coactivator Activity 8x10-5 0.03 
  Transcriptional Activity of SMAD2, SMAD3, SMAD4,   
     Heterotrimer 
0.0001 0.03 
  Zinc Ion Binding 0.0002 0.04 
  Other RNA Binding Protein 0.0002 0.04 
  Insulin-like Growth Factor-2 mRNA Binding Proteins  
     (IGF2BPS/IMPS/VICKZS) 
0.0003 0.05 
 Trans-Ethnic General RNA Polymerase II Transcription 4x10-6 0.006 
  Transcription 4x10-5 0.03 
JT African American Transcription Factor TFIID Complex 7x10-5 0.05 
  Aminoacyl-tRNA Synthetase Multienzyme Complex 0.0001 0.05 
  tRNA Aminoacylation for Protein Translation 0.0001 0.05 
  Transcription Factor TFTC Complex 0.0001 0.05 
 Trans-Ethnic Transciption 3x10-5 0.03 
  General RNA Polymerase II Transcription Factor Activity 4x10-5 0.03 
Abbreviations: FDR, False discovery rate; JT, JT interval; P, P-value; QT, QT interval 
 



